- cafead Sep 25, 2024 at 10:42: PM
via Celldex (NASDAQ:CLDX) Therapeutics, Inc. (NASDAQ:CLDX) has announced sustained efficacy and a well-tolerated safety profile for barzolvolimab after a 52-week treatment period in patients with chronic spontaneous urticaria (CSU). The data, presented at the EADV Congress 2024, showed that 71% of patients receiving barzolvolimab 150 mg every four weeks achieved a complete response at Week 52.
article source
article source